Month: August 2025

Sportradar Reports Second Quarter Financial Results and Raises Full Year 2025 Outlook

Written by Customer Service on August 5, 2025. Posted in Earnings Releases And Operating Results.

Second Quarter 2025 HighlightsRevenue increased 14% to a record €318 million Profit for the period increased to €49 million and expanded to 15.5% as a percentage of revenue Adjusted EBITDA1 increased 31% to €64 million and Adjusted EBITDA margin1 expanded to 20.1% Net cash generated from operating activities increased 14% to €97 million and Free cash flow1 was €52 million Achieved a Customer Net Retention Rate1 of 117% Repurchased $65.5 million of shares under the share repurchase plan Raised full year outlook to revenue of at least €1,278 million, or 16% growth and Adjusted EBITDA of at least €284 million, or 28% growth.ST. GALLEN, Switzerland, Aug. 05, 2025 (GLOBE NEWSWIRE) — Sportradar Group AG (NASDAQ: SRAD) (“Sportradar” or the “Company”), a leading global sports technology company focused on creating immersive experiences...

J & J Snack Foods Reports Fiscal 2025 Third Quarter Results

Written by Customer Service on August 5, 2025. Posted in Earnings Releases And Operating Results.

MOUNT LAUREL, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) — J & J Snack Foods Corp. (NASDAQ: JJSF) (the “Company”) today reported financial results for the third quarter ended June 28, 2025. Third Quarter Actuals $ vs. LY % vs. LYNet Sales $454.3M $14.3M 3%Gross Profit $150.0M $2.3M 2%Operating Income $60.6M $10.5M 21%Net Earnings $44.2M $7.9M 22%Earnings per Diluted Share $2.26 $0.39 21% Adjusted Operating Income $53.4M $0.4M 1%Adjusted EBITDA $72.0M $1.2M 2%Adjusted Earnings per Diluted Share $2.00 $0.02 1% This press release contains non-GAAP financial measures. Please refer to the Non-GAAP Financial Measures section below for reconciliations to the most comparable GAAP measures. Dan Fachner, J&J Snack Foods Chairman, President, and CEO stated, “We delivered strong...

Exodus Movement, Inc. July 2025 Treasury Update and Monthly Metrics

Written by Customer Service on August 5, 2025. Posted in Public Companies.

July MAUs reach 1.7 million; Treasury contains 2,087 BTC OMAHA, Neb., Aug. 05, 2025 (GLOBE NEWSWIRE) — Exodus Movement, Inc. (NYSE American: EXOD) (“Exodus” or “the company”), a leading self-custodial cryptocurrency platform, today announced an update to selected digital asset holdings of Exodus’ corporate treasury, as well as updated user and exchange provider processed volume metrics, as of July 31, 2025: Selected Digital Asset Holdings (Unaudited)Bitcoin (BTC): 2,087 BTC as of July 31, 2025 compared to 2,058 as of June 30, 2025Ethereum (ETH): 2,742 ETH as of July 31, 2025 compared to 2,729 as of June 30, 2025Solana (SOL): 34,578 SOL as of July 31, 2025 compared to 31,823 as of June 30, 2025 UsersMonthly Active Users (MAUs): 1.7 million as of July 31, 2025, of which approximately 20,000 are Passkeys wallets. That...

Neuronetics Reports Second Quarter 2025 Financial and Operating Results

Written by Customer Service on August 5, 2025. Posted in Earnings Releases And Operating Results.

Delivered $38.1 million total revenue in the quarter, representing 18% adjusted pro forma revenue growth Generated record Greenbrook clinic revenue of $23.0 million in the quarter Reduced cash used in operations to $3.5 million, beating guidance of under $5 million In August 2025, received an additional $10 million in funding under the existing debt agreement with Perceptive Advisors LLC MALVERN, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) — Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its financial and operating results for the second quarter of 2025. Second Quarter...

Xometry Reports Record Second Quarter 2025 Results

Written by Customer Service on August 5, 2025. Posted in Earnings Releases And Operating Results.

Q2 revenue increased 23% year-over-year to a record $163 million driven by robust marketplace growth. Q2 marketplace revenue increased 26% year-over-year driven by strong enterprise growth and expanding networks of buyers and suppliers. Q2 gross profit increased 23% year-over-year to a record $65.2 million, or 40.1% of revenue driven by record marketplace gross margin of 35.4%. Q2 Adjusted EBITDA improved $6.6 million year-over-year to Adjusted EBITDA of $3.9 million driven by expanding marketplace gross margin and strong operating expense leverage. Strong operating results are driven by consistent execution across growth initiatives: expanding buyer and supplier networks; driving deeper enterprise engagement; further expanding the marketplace platform; growing internationally and enhancing supplier services.NORTH BETHESDA, Md., Aug....

AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Written by Customer Service on August 5, 2025. Posted in Public Companies.

AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate UpdateThree active immunotherapies for precision prevention of neurodegeneration progressing through Phase 2 clinical development ACI-7104.056 anti-alpha-synuclein active immunotherapy in Parkinson’s disease produced strong immunogenicity and favorable safety profile in interim results from the ongoing Phase 2 VacSYn reported in April, with further data to come in H2 2025 Third Alzheimer’s disease cohort (AD3) in the Phase 2 ABATE trial of anti-Abeta ACI-24.060 to reach 12 months of treatment in December 2025, with interim results expected early 2026 Small molecule NLRP3 program now in IND-enabling studies, highlighting promise in early-stage pipeline Cash resources of CHF 127.1 million (USD157.6 million) as of June 30, 2025, provide funding into Q1 2027...

Iterum Therapeutics Reports Second Quarter 2025 Financial Results

Written by Customer Service on August 5, 2025. Posted in Public Companies.

–– Launch of ORLYNVAHTM Expected August 2025— –-Cash Runway into 2026– –Company to host conference call today at 8:30amET– DUBLIN and CHICAGO, Aug. 05, 2025 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the second quarter ended June 30, 2025. “We are on track to launch ORLYNVAH™ this month for the treatment of uncomplicated urinary tract infections (uUTIs),” said Corey Fishman, Chief Executive Officer of Iterum Therapeutics. “We’re proud to introduce the first branded antibiotic for uUTIs in over 25 years—a critical milestone as rising antimicrobial resistance...

Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

Written by Customer Service on August 5, 2025. Posted in Public Companies.

SAN MATEO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025, at 2 p.m. EDT in Boston, MA. A webcast of the fireside chat will be available in the Investors & Media section of Sagimet’s website at www.sagimet.com, with an archived replay available for 90 days following the live event. About Sagimet Biosciences Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from...

Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update

Written by Customer Service on August 5, 2025. Posted in Public Companies.

FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population, is enrolling well and remains on track Preclinical synergistic benefit of FHD-909 in combination with pembrolizumab and KRAS inhibitors reinforces significant potential in NSCLC Selective CBP degrader on track for IND-enabling studies, targeting an IND in 2026 Continued progress on Selective EP300 degrader and Selective ARID1B degrader, with program updates expected in Q4 2025 Strong balance sheet with cash, cash equivalents, and marketable securities of $198.7 million as of June 30, 2025; cash runway into 2028 CAMBRIDGE, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines...

Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates

Written by Customer Service on August 5, 2025. Posted in Public Companies.

Second-quarter 2025 Rezdiffra™ (resmetirom) net sales of $212.8 million As of June 30, 2025, more than 23,000 patients on Rezdiffra Received new U.S. Rezdiffra patent providing protection to Feb. 4, 2045 Announced global licensing agreement for an oral GLP-1 development candidate In July, secured up to $500 million in senior secured credit to advance pipeline Presented compelling two-year F4c data at EASL Congress; provides estimates for U.S. F4c MASH patient population Received positive CHMP opinion recommending approval of Rezdiffra for the treatment of MASH in Europe Appointed Dan Brennan to Board of Directors Reports cash, cash equivalents, restricted cash and marketable securities of $802.0 million as of June 30, 2025 Company to host conference call today, Aug. 5, 2025, at 8 a.m. EDTCONSHOHOCKEN, Pa., Aug. 05, 2025...

Month: August 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals